Results 31 to 40 of about 4,590 (196)
BMC Endocrine Disorders, 2012 Background The uncertainties regarding dose similarities between basal long-acting insulin analogues remain. Recent real-world studies indicate dose similarities between insulin detemir and insulin glargine, but further studies are still warranted.
Jakobsen Marie +3 more
doaj +1 more source
Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. [PDF]
PLoS ONE, 2014 To compare the commonly prescribed oral anti-diabetic drug (OAD) combinations to use as an add-on therapy with insulin glargine in patients with uncontrolled type 2 diabetes despite submaximal doses of OADs.People with inadequately controlled type 2 ...
Cheol-Young Park +6 more
doaj +1 more source
Insulin glargine use and breast cancer: a systematic review and meta-analysis
Electronic Physician, 2019 Background: Insulin is widely used in the treatment of diabetes. There is an increasing concern regarding the association between insulin glargine use and breast cancer.
Ibrahim Altedlawi Albalawi +1 more
doaj +1 more source
Journal of Diabetes Research, 2021 Insulin treatment was confirmed to reduce insulin resistance, but the underlying mechanism remains unknown. Caveolin-1 (Cav-1) is a functional protein of the membrane lipid rafts, known as caveolae, and is widely expressed in mammalian adipose tissue ...
Hangya Peng +8 more
doaj +1 more source
Pakistan Armed Forces Medical Journal, 2023 Objective: To compare the efficacy of Glargine Insulin with Neutral Protamine Hagedorn (NPH) Insulin in patients with uncontrolled type 2 diabetes with oral hypoglycemic. Study Design: Prospective cohort study.
Ebtihal Bilal +4 more
doaj +1 more source
Cost Effectiveness and Resource Allocation, 2019 Background International guidelines recommend using basal insulin in patients with type-2 diabetes mellitus if glycaemic target cannot be attained on non-insulin anti-diabetic drugs.
E. Lau +6 more
doaj +1 more source
Electronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulin. [PDF]
PLoS ONE, 2014 Recent studies suggested that insulin glargine use could be associated with increased risk of cancer. We compared the incidence of cancer in new users of glargine versus new users of NPH in a longitudinal clinical cohort with diabetes for up to 6 years ...
Soo Lim +8 more
doaj +1 more source
Optimal Regulation of Blood Glucose Level in Type I Diabetes using Insulin and Glucagon [PDF]
, 2018 The Glucose-Insulin-Glucagon nonlinear model [1-4] accurately describes how the body responds to exogenously supplied insulin and glucagon in patients affected by Type I diabetes. Based on this model, we design infusion rates of either insulin (monotherapy) or insulin and glucagon (dual therapy) that can optimally maintain the blood glucose level ...
arxiv +1 more source
Diabetes, Obesity and Metabolism, 2016 AimsLY2963016(LY IGlar) and Lantus (IGlar) are insulin glargine products manufactured by distinct processes, but with identical amino acid sequences. This study compared the duration of action ofLY IGlarandIGlarin subjects with type 1 diabetes mellitus (T1DM).Materials and methodsThis was a randomized, double‐blind, single‐dose, two‐period, crossover ...
Christoph Kapitza +7 more
openaire +3 more sources
Impairment of insulin-stimulated glucose utilization is associated with burn-induced insulin resistance in mouse muscle by hyperinsulinemic-isoglycemic clamp [PDF]
arXiv, 2020 Burn-induced insulin resistance is associated with increased morbidity and mortality; however, the impact of burn injury on tissue-specific insulin sensitivity and its molecular mechanisms with consideration of insulin state remains unknown in rodent models.
arxiv